Nice press release but it's not going to take us to $2 by the end of the month without any sales numbers.
December 04, 2013 12:02 AM Eastern Standard Time
HUBBARD, Ohio--(BUSINESS WIRE)--NanoLogix, Inc. (NNLX), an innovator in the rapid detection, identification of live bacteria, and determination of their antibiotic resistance and sensitivity, announces that they are working with Nasaem-Aljazira, a Saudi Arabian company headquartered in Riyadh, to establish exclusive distribution and/or manufacturing of NanoLogix products in Saudi Arabia and the Arabian Gulf region, also known as the Gulf Cooperation Council (GCC) area.
This area offers a large market potential to Nasaem-Aljazira and NanoLogix, with Saudi Arabia being a leader in advanced health care initiatives for its people.
NanoLogix is also in negotiations with groups and companies in Europe, Asia and Africa on additional distribution outlets and manufacturing options.
The Company currently sells and ships its products in the US and to the UK.
So based on increases of those four, ADXS could go anywhere from $8 to $24. I'm hoping for the high end as my break even is $18...been around too long and am not a trader...old school buy and hold.
IMO, they have been trying to keep the sp around $5 or better to make the offering at $4 that much more attractive to institutional investors. Waiting for greater news to come.
Dump the pig, AEMD is ahead of us now:
SAN DIEGO, Oct. 15, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce.
In recent months, we launched and staffed a diagnostic subsidiary, expanded our intellectual property portfolio, and continued to generate revenues from established and newly awarded government contracts. More importantly, we achieved the most significant milestone in the history of our organization, FDA approval of an investigational device exemption (IDE) that allows us to initiate the first human Hemopurifier® therapy studies in the United States. As a result, we have an opportunity to reward our stakeholders though the established Wall Street model of demonstrating U.S. clinical progression. For those not familiar with our Hemopurifier®, it is a first-in-class medical device that targets the rapid elimination of life-threatening infectious viruses and cancer glycopathogens from circulation.
As per the IDE approved protocol, we will enroll ten end-stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the protocol, which we previously conducted with success in India, will set the stage for pivotal studies required for market clearance in the U.S. The approval of our IDE has also unlocked the ability to advance clinical partnering programs with medical institutes that are pursuing indications of our Hemopurifier® in cancer care.
Manufacturing Optimization and Ramp-up
In the coming weeks, we are scheduled to initiate Hemopurifier® manufacturing to support our FDA approved study as well as our continued treatment endeavors overseas. In this regard, I am pleased to share that our researchers along with collaborative assistance have disco
Why all the selling on almost triple avg vol today.... newbies from previous run-up bailing on disappointment? Where's Parents, still in Switzerland? Yodal-lay-he-hooo? No? Nothing? How 'bout Marco?
Hey, don't diss the Browns commish. They haven't been .500 or better this early in the season for a long time. Don't expect them to win the division but I'll take 2 and 2 right now.... better than the putzy Steelers at 0 and 4.
Good question commish. You'd think all agencies you mentioned would be interested, especially the USDA with all the salmonella incidents the past couple of years.
And the shares outstanding will continue to grow, the market cap will continue to grow, and dilution will continue to grow. Tom should have been gone at least 2 years ago. My fear is that Dan the man was brought on board too late. JMHO. Watch for more S.A. articles, sell on the pump and buy on the dump.
And yet the pps remains the same :(